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Purpose: Contrast sensitivity (CS) testing is an important measure of visual function
reflecting variations in everyday visual experience in different conditions and helps to
identify more subtle vision loss. However, it is only infrequently used. To make this
more accessible, we have developed and validated a smartphone-based CS test.
Methods: A new tumbling-E smartphone-based CS test was developed, Peek Contrast
Sensitivity (PeekCS). This was field tested and refined through several iterations.
Reference standard was a tumbling-E Pelli-Robson CS test (PRCS). The validation study
was conducted in community clinics in Ethiopia. Test-retest variability was measured
for both PRCS and PeekCS. PRCS and PeekCS were then compared. Correlation
coefficients and 95% confidence intervals (CIs) were calculated; 95% limits of
agreement were calculated and displayed on Bland-Altman plots.
Results: PeekCS showed strong repeatability (correlation coefficient: 0.93; 95% CI:
0.91–0.95), which was comparable with PRCS (correlation coefficient: 0.96; 95% CI:
0.95–0.97). The 95% limit of agreement for test-retest variability of PRCS and PeekCS
were 0.20 to 0.21 and 0.31 to 0.29, respectively. PRCS and PeekCS were highly
correlated: 0.94 (95% CI: 0.93–0.95); 95% limits of agreement 0.27 to 0.29; and mean
difference 0.010 (95% CI: 0.001 to 0.022). PeekCS had a faster testing time (44.6
seconds) than PRCS (48.6 seconds): mean difference 3.98 (95% CI: 5.38 to 2.58);
P , 0.001.
Conclusions: The smartphone-based PeekCS is a repeatable and rapid test, providing
results that are highly comparable with the commonly used PRCS test.
Translational Relevance: PeekCS provides an accessible and easy to perform
alternative for CS testing, particularly in the community setting.
Introduction
Visual acuity (VA) is the most frequently per-
formed measure of visual function. In a VA test,
optotypes of decreasing size with a fixed high contrast
level are presented. However, high contrast does not
always reflect performance in real world situations.
Contrast sensitivity (CS), an important measure of
visual function, is the ability to detect a difference
between the luminance of an object and its back-
ground.1,2 The varying levels of contrast presented in
a CS test more accurately represent variations
common to everyday visual experience.3,4
Poor CS degrades quality of vision, by reducing the
ability to distinguish between objects without distinct
outlines, affecting day to day activities even in people
with normal VA.1,3,5–8 CS is a useful measure of visual
function in evaluating patients with cataract, glauco-
ma, diabetic retinopathy, and macular degenerations;
the leading causes of blindness worldwide.9–12 It is also
an important measure of visual function for occupa-
tions requiring particularly good eye sight. Poor CS
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can significantly limit activity and reduce quality of
life.2,12 In a recent study from Ethiopia, poor CS was
strongly associated with reduced quality of life scores
in patients with trachomatous trichiasis.13
CS tests usually involve letters of a fixed size,
which gradually become lighter through the test, until
they are almost identical to background and impos-
sible to detect.1,14 There are several chart and
computer-based CS tests. Perhaps the most widely
used is the Pelli-Robson Contrast Sensitivity (PRCS)
test.14 This provides a reliable and repeatable measure
of low spatial frequency CS, tested at 1 meter. It has
been used in multiple studies as the reference standard
for evaluating other CS tests.15,16 The PRCS chart
can be produced in a ‘‘tumbling E’’ format for use in a
context with a low literacy level.
CS is infrequently measured in routine clinical
practice, for several reasons: lack of familiarity, time
constraints, interpretation difficulty or unavailability.
PRCS is large and needs careful handling; therefore, it
is less easy to use in outreach clinics. Other tests of
CS, such as the Spaeth/Richman Contrast Sensitivity
(SPARCS) test, require a computer with internet
access, making them impractical for outreach or a low
resource setting.15,16
Increased availability of smartphones is transform-
ing vision measurement and access to eye care services
in hard to reach low-income settings.17 Peek Vision is
developing smartphone-based tools to address these
needs (https://www.peekvision.org). The Peek Acuity
app, which measures distance VA, has been found to be
repeatable and reliable.17 Furthermore, the app’s
inclusion in a community vision screening program in
rural Kenya demonstrated the robustness of smart-
phone-based tests in such settings as well as their ability
to remain charged throughout an entire day’s testing.
Various mobile electronic device based CS tests
have been studied and developed.18–25 However, all of
the tests designed for mobile devices were written for
iOS and validated using Apple (Cupertino, CA)
products.18–24 As of June 2019, the most basic models
of the latest Apple smartphone, tablet, and MP4 player
models (the iPhone 8, iPad, and iPod Touch) were 600,
400, and 200 USD, respectively (www.apple.com).
Such costs are prohibitive for at-scale use in low-
resource settings. As such these tend to represent a
small fraction of the mobile device market in low-
income countries, with Apple accounting for less than
4% of the mobile phone market in Ethiopia, for
example (http://gs.statcounter.com/vendor-market-
share/mobile/ethiopia). Smartphones running the An-
droid operating system are widespread and constitute
the vast majority of the market in low-income
countries. They are also comparatively inexpensive
with devices being available for under 26 USD (www.
walmart.com/ip/Tracfone-Alcatel-Raven-Prepaid-
Smartphone/613852626). A CS test designed for
Android devices is therefore necessary if such a test is
to be sustainably introduced into clinical practice at
scale in low-income countries. Furthermore, the
aforementioned studies were each conducted in high
resource settings in relatively small numbers of
participants, with all but one having n  40. A
smartphone-based CS test designed for and validated
in a low-income country is therefore desirable.
In addition, most of these studies used either Quick
CSF (a computerized monitor-based test from a
Bayesian adaptive procedure) or swept-frequencies
or gratings, which probably are not as familiar as
optotype-based tests either to a nonliterate patient or
primary health care professional in a resource-limited
setting, owing to their similarity to established VA
tests. Moreover, there is limited evidence on the
validity and applicability of the various commercially
available mobile device-based CS test applications in
nonliterate communities. Furthermore, subtle differ-
ences in testing methods such as viewing distance and
lighting conditions, or size and screen brightness of
different devices, or the variability of settings
including the awareness and skill of the persons being
tested and doing the test would provide varying
results and would affect reliability of CS tests,
indicting that more CS tests and applications need
to be developed using various methods and in
different settings. There is a need for a relatively
simple and easy to use CS testing method, particularly
by health cadres with limited training in community-
based efforts, to streamline comprehensive eye care
service delivery.
In this study, we developed a new smartphone-
based CS test and validated relative to the PRCS test
for use at any level of the health care system,
particularly in low-resource settings, and validated
this in a study population with a low level of literacy.
We refer to this new test as Peek Contrast Sensitivity
(PeekCS). The rationale was to produce a smartphone
CS test with sufficient accuracy to make CS testing
much more widely available, easier, and potentially
faster to perform across all settings.
Methods
This study was conducted in Ethiopia. It was
approved by Ethiopian National Health Research
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Ethics Review Committee, London School of Hygiene
& Tropical Medicine Ethics Committee, and Emory
University Institutional Review Board. It was con-
ducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained
from all participants in Amharic before enrolment.
Illiterate participants were read the information sheet
and consent form; their consent was recorded by
thumb print in the presence of a witness. This study
was nested within a previously reported randomized
placebo controlled trial of oral doxycycline for the
prevention of postoperative trichiasis.26
Study Participants
Participants enrolled into the clinical trial were
identified through community-based screening, and
by organizing community-based surgical outreaches
in health facilities in West Gojjam Zone, Amhara
Region. Detailed methodology for identification,
recruitment, and follow-up of participants has been
previously described.26 In summary, adults .18 years
with trachomatous trichiasis were identified, received
surgical treatment, and immediately randomized to
receive either oral doxycycline 100 mg per day for 28
days or placebo capsules. Follow-up was conducted at
10 days, and at 1, 6, and 12 months to examine for
postoperative trichiasis, corneal opacity, and vision
change. The CS test development and validation were
conducted during the final 12-month follow-up. The
data from the final validation were collected between
April 4, and May 7, 2017.
PeekCS Test Development
The development of the smartphone-based PeekCS
test went through multiple stepwise iterations. The
development process is described in the Supplemen-
tary Material. Within each development cycle, we
tested performance in a new group of study partic-
ipants. As the reference test, we used two separate 1-
meter ‘‘Tumbling – E’’ PRCS charts (Precision Vision,
Woodstock, IL) ordered and made specifically for use
in this study population with low literacy level,
following the standard instruction and described in
the Supplementary Material.
Final PeekCS Test
The final PeekCS test version was performed using
a Sony Xperia Z3 (Android 4.4). The settings for each
CS are shown in Table 1. The smartphone was
Table 1. The RGB Values Used in the PeekCS Testa
Score Stage
Optotype Gray
RGB Value
Background Gray
RGB Value
Actual Peek
CS Log10 (CS)
Standard
Error
Pelli-Robson
Log10 (CS) Contrast
1 0 255 0.006 0.000007 0.00 Highest
2 164 255 0.20 0.00040 0.15 E
3 197 254 0.35 0.000625 0.30
4 216 255 0.50 0.00026 0.45
5 229 255 0.65 0.001225 0.60
6 237 255 0.78 0.00306 0.75
7 242 254 0.96 0.00208 0.90
8 246 255 1.06 0.03935 1.05
9 248 255 1.16 0.0017 1.20
10 250 254 1.40 0.01185 1.35
11 250 253 1.53 0.0184 1.50
12 252 255 1.67 0.00475 1.65
13 246 248 1.71 0.00875 1.80
14 252 254 1.94 0.0034 1.95
15 254 255 2.00 0.0076 2.10 E
16 N/A N/A N/A N/A 2.25 Lowest
N/A, not applicable; RGB, red, green, blue.
a Designed for a Sony Xperia Z3 for each Score Stage and the corresponding actual CS measured by a photometer in a
darkened laboratory setting. Owing to the finite combinations of optotype and background grays, it is not possible to have
an exact alignment between the contrast sensitivities tested with PeekCS and the Pelli-Robson charts. However, the
difference between the two tests is never more than two-thirds of the difference between score stages (i.e., 0.10 log units).
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mounted on a tripod with a ‘‘Twist Grip’’ clamp. Eyes
were tested separately at 1 meter. Screen brightness
was set to 100%. One letter ‘‘E’’ was displayed at a
time in one of four random orientations. The tester
swiped the screen in the direction the participant
indicated, to record the response. The test logic and
method are described in detail in Online Supplemen-
tary Material and Figure S2. At the end of the test,
the application displays the log CS result.
Validation Procedures
All CS tests were conducted prior to any ocular
examination. Four CS tests were performed for each
eye separately: two PRCS (different charts) and two
PeekCS. Each test was completed for right eye and
then left eye before doing the next test. Test order was
chosen at random using a computer-generated ran-
dom table. The four possible testing orders were: (1)
PeekCS1, PRCS1, PeekCS2, PRCS2; (2) PRCS1,
PeekCS1, PeekCS2, PRCS2; (3) PeekCS1, PRCS1,
PRCS2, PeekCS2; (4) PRCS1, PeekCS1, PRCS2,
PeekCS2. A single health officer conducted both tests
in the same room with adequate natural light.
Ambient light was measured using an ISO-TECH
ILM 1332A Lux meter for the adjacent places where
the Pelli-Robson charts and smartphone were posi-
tioned for testing. The PeekCS app also displays an
alert if the phone’s integrated light sensor detected an
ambient light level exceeding 900 lux. Participants
were given sufficient time to identify the direction of
each letter, particularly when near threshold. VA was
measured. Eyes were examined with 2.53 loupes and
torch for signs related to trachoma including trichiasis
and corneal opacification. The detailed examination
methodology has been previously described.26
Statistical Analysis
Data were double-entered into Access (Microsoft),
cleaned, and transferred to Stata 14.2 (StataCorp) for
analysis. Demographic and clinical data were sum-
marized using means and proportions. Data from
both right and left eyes are used in this analysis.
Test-retest variability was analyzed for PRCS1
versus PRCS2 and PeekCS1 versus PeekCS2. PRCS
was compared with PeekCS by combining the first
and second test pairs of each. Correlation coefficients
and 95% CIs were generated to determine linear
relationship between tests. Scatter plots were used to
plot the distribution comparisons between tests.
Bland-Altman plots were generated from the individ-
ual’s mean CS score measured by the two tests being
compared and the difference in CS between the two
test results. The 95% CI limits of agreement were
calculated as the mean difference between tests6 1.96
multiplied by the standard deviation of the mean
differences.27 Mean differences in CS, test times, and
room brightness were estimated using mixed effect
linear regression models. A mixed effect model was
used to account for the fact that each participant
contributed CS tests from both eyes, and when
comparing PeekCS and PRCS, each eye contributed
two CS tests, so the model included random intercepts
for both patient and eye, with eye nested within
patient.
Results
CS was measured using two PRCS charts and the
final version of PeekCS for 147 individuals (294 eyes).
Demographic and clinical characteristics are de-
scribed in Table 2. Participants had a mean age of
50.3 years (range, 18–82 years) and were predomi-
nantly female (110/147 [74.8%]) and illiterate (128/147
[87.1%]). All participants had received corrective
upper eyelid surgery for trachomatous trichiasis in
at least one eye 12 months prior to this data
collection: 50 (34%) right eyelid surgery only, 73
(49.7%) left eyelid surgery only, and 24 (16.3%) both
eyelids. Overall, 171/294 (58.2%) of the eyes tested for
CS had previously undergone trichiasis surgery.
Among the 294 eyes, 67 (22.8%) had trichiasis at 12
months, of which the majority (60/67 [89.5%]) were
minor trichiasis (one to five lashes touching the eye).
Some degree of corneal opacity was reported in two
thirds of eyes (Table 2). In 69 (32.5%) eyes, there was
central corneal opacity and 60 (20.4%) eyes had off
center opacities, encroaching within the central 4 mm.
Eight (2.7%) eyes had easily visible mature cataract.
VA was impaired in 101 (34.4%) eyes (Table 2).
The comparison between the four tests repeatabil-
ity and correlation results are presented in Table 3.
The PRCS test had very strong test-retest character-
istics with a correlation of 0.96 (95% CI: 0.95–0.97)
and no evidence of systematic difference in mean
(‘‘bias’’) between the two tests (mean difference: 0.004;
95% CI: 0.008 to 0.016). The scatter plot (Fig. 1a)
shows that the fitted line is very close to the line of
equality. The 95% limits of agreement in the Bland-
Altman analysis (Fig. 1b) were between 0.20 and
0.21, indicating that in 95% of repeated tests the
difference would be less than two PRCS steps. In this
analysis, 59.5% of paired observations were identical,
and a further 37.4% scored only one step difference.
4 TVST j 2019 j Vol. 8 j No. 5 j Article 13
Habtamu et al.
PeekCS showed strong repeatability with a corre-
lation of 0.93 (95% CI: 0.91–0.95). There was no
evidence of bias between the two PeekCS tests (mean
difference: 0.012; 95% CI: 0.030 to 0.005). The
scatter plot and Bland-Altman for PeekCS repeat-
ability are shown in Figures 1c and 1d. The 95% limit
of agreement between PeekCS1 and PeekCS2 were
slightly wider than the PRCS tests at 0.31 to 0.29.
This is roughly equivalent to two PRCS steps, with
38.4% of paired observations being identical, and a
further 50.7% scoring only one step difference
between the two PeekCS tests.
Combining the two sets of PRCS versus PeekCS
comparisons (PRCS1 versus PeekCS1 and PRCS2
versus PeekCS2) found a high degree of correlation
0.94 (95% CI: 0.93–0.95) (Table 3). The Bland-
Altman 95% limits of agreement were 0.27 and
0.29, equivalent to two PRCS steps; with 45.6% of
paired observations being identical, and a further
44.7% scoring only one step difference between the
two tests (Fig. 2). The estimated mean difference
between PRCS and PeekCS was 0.010 (95% CI:
0.001 to 0.022), with the slightly higher mean score
in PRCS. The upper bound of this CI represents only
approximately one-seventh of a PRCS step.
Test time for PeekCS was faster than PRCS: mean
PRCS test time was 48.6 seconds and PeekCS was
44.6 seconds (mean difference: 3.98; 95% CI: 5.38
to2.58; P , 0.001). The second round of testing was
significantly faster for both PRCS (PRCS1 versus
PRCS2 mean difference: 8.29; 95% CI: 9.63 to
6.94; P ¼ ,0.0001) and PeekCS (PeekCS1 versus
PeekCS2 mean difference: 7.41; 95% CI: 9.34 to
5.49; P ¼,0.0001).
There was no difference in mean room illuminance
between the first and the second PeekCS tests (mean
303.7 lux versus 304.2 lux; mean difference: 0.46; 95%
CI:4.86 to 5.78; P¼ 0.865) and the first and second
PRCS tests (mean 294.2 lux versus 297.6 lux; mean
difference: 3.45; 95% CI: 2.18 to 9.07; P ¼ 0.230).
The average room brightness was slightly higher for
PeekCS compared with PRCS (mean difference: 8.06
lux; 95% CI: 3.48–12.64; P ¼ 0.001).
The white areas of the PRCS test charts have a
reflectance of 69.8%,28,29 and thus the luminance of
these areas can be approximated to the illuminance
multiplied by the reflectance divided by pi (that is
mean luminances of 65.4 and 66.1 cd/m2; mean
difference: 0.77; 95% CI: 0.48 to 2.02). The
background luminance of the chart was therefore
within a range for which the CS of the participant is
known not to vary from that measured at the
manufacturer’s recommended background luminance
of 85 cd/m2 (www.precision-vision.com/product/pelli-
robsonsloanlettercontrastchart), owing to effects such
as pupil miosis.29
The reflectance of the Sony Xperia Z series display
has been measured to be approximately 5.6% (http://
www.displaymate.com/Smartphone_ShootOut_3.
Table 2. Demographic and Clinical Characteristic of
Participants
Characteristics No. (%)
Demographic, n ¼ 147
Age, mean 6 SD, y 50.3 6 13.7
Female 110 (74.8)
Illiterate 128 (87.1)
Eye, n ¼ 294
VA
Normal (6/18) 193 (65.6)
Moderate visual impairment
(,6/18 to 6/60)
95 (32.3)
Severe visual impairment
(,6/60 to 3/60)
2 (0.7)
Blind (,3/60) 4 (1.4)
Previous trichiasis surgery
No 123 (41.8)
Yes 171 (58.2)
Trichiasis (number of lashes
currently touching eye)
No trichiasis 227 (77.2)
None (epilating) 3 (1.0)
1–5 57 (19.4)
6–9 5 (1.7)
10–19 2 (0.7)
Corneal opacity
None (CC0) 99 (33.7)
Peripheral (CC1)a 66 (22.5)
Off center, faint (CC2a)b 57 (19.4)
Off center, dense (CC2b)b 3 (1.0)
Central, faint (CC2c)c 60 (20.4)
Central, dense (CC2d)c 9 (3.1)
Total central, dense (CC3) 0 (0.0)
Phthisis (CC4) 0 (0.0)
Faint indicates pupil margin is visible through the
opacity; dense indicates the pupil margin is not visible
through the opacity.
a Peripheral is outside the central 4 mm.
b Off center is within the central 4 mm but does not
involve the central 1 mm.
c Central involves the central 1 mm of the cornea.
5 TVST j 2019 j Vol. 8 j No. 5 j Article 13
Habtamu et al.
htm). This implies that reflection of ambient light
contributes approximately an added 5.4 cd/m2 to
screen luminance, that is 5.6% of the illuminance
divided by pi. The overall effect on brightness is
therefore marginal.
The effect of such a reflection, if assumed to be
uniform across the display, can be determined by re-
calculating the log contrast sensitivities of each stage
after adding 5.4 cd/m2 to the luminances measured in
darkness. In each instance, this resulted in an increase
in the CS measured by 0.009 log units. The effect of
ambient light at the levels measured was therefore
marginal; indeed PeekCS is less sensitive to fluctua-
tions in ambient light than the Pelli-Robson chart and
thus was disregarded in our subsequent analysis.
Discussion
There are approximately 253 million persons with
distance visual impairment worldwide.30 This number
is based on standard VA measurement. It probably
underestimates people who experience impaired visual
function due to reduced CS.3 The current demo-
graphic trends of aging populations and increasing
obesity will probably substantially increase in the
global burden of visual impairment from macular
degeneration, glaucoma, and diabetic retinopathy,
conditions known to impair CS.9–11,30 Early detection
of these conditions allows clinicians to intervene
against sight loss.
CS is a sensitive measure of visual defects in
glaucoma and is able to discriminate the severity of
diabetic retinopathy and cataract.10–12,31 The tradi-
tional VA measure may not correlate well with day-
to-day visual challenges that a person experiences or
identify gradual neuropathological visual function
changes.5,32–34 CS testing provides a measure of visual
function that perhaps more readily reflects visual
function in the ‘‘real world’’ and helps to identify
more subtle or gradual vision loss.3,5,33,34 Some
people, particularly at an older age, may have normal
VA but reduced CS.1,3
Table 3. Repeatability and Correlation of CS Testsa
Tests Mean (95% CI) Mean Difference (95% CI) 95% Limit of Agreement
PRCS1 vs. PRCS2
PRCS1 1.407 (1.349 to 1.465) 0.004 (0.008 to 0.016) 0.20 to 0.21
PRCS2 1.403 (1.345 to 1.461)
PeekCS1 vs. PeekCS2
PeekCS1 1.389 (1.328 to 1.450) 0.012 (0.030 to 0.005) 0.31 to 0.29
PeekCS2 1.401 (1.340 to 1.462)
PRCS vs. PeekCSb
PRCS 1.405 (1.346 to 1.464) 0.010 (0.001 to 0.022) 0.27 to 0.29
PeekCS 1.395 (1.336 to 1.454)
a All analyses are adjusted for bilateral eye data using mixed effects models.
b Combined analysis of the first and second PRCS and PeekCS pairs, adjusted using mixed effects models.
Table 3. Extended
Tests Pearson Correlation Coefficient (95% CI) Intraclass Correlation Coefficient (95% CI)
PRCS1 vs. PRCS2
PRCS1 0.96 (0.95 to 0.97) 0.96 (0.95 to 0.97)
PRCS2
PeekCS1 vs. PeekCS2
PeekCS1 0.93 (0.91 to 0.95) 0.93 (0.91 to 0.95)
PeekCS2
PRCS vs. PeekCSb
PRCS 0.94 (0.93 to 0.95) 0.94 (0.92 to 0.95)
PeekCS
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Figure 2. (A) Scatter plot and (B) Bland-Altman plot for PRCS and PeekCS.
Figure 1. Scatter and Bland-Altman plots for test-retest: (A, B) Pelli-Robson CS (PRCS1 versus PRCS2) and (C, D) Peek Contrast Sensitivity
(PeekCS1 versus PeekCS2).
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Therefore, it is helpful to combine measurement
CS with VA in clinical practice to obtain a more
complete picture of visual function.3 However, CS is
infrequently measured in routine clinical practice.
This is particularly the case in low- and middle-
income settings. The testing of CS requires training,
equipment, and time. CS tends to be mostly used in
research settings or specialist, very well-resourced
clinics. Therefore, there is a need for a low-cost,
accessible, quick, and easy to use CS test to enable
more widespread use.
Increasing availability of smartphones, including
in low and middle-income countries, provides a new
opportunity to deliver CS testing. We have previously
developed, tested, and released a smartphone-based
application to test distance VA, Peek Acuity.17 This
has been downloaded free of charge by more than
50,000 people in more than 140 countries. It is being
used in teacher-delivered school-based screening
programs to identify children in need of eye care
services.35 Encouraged by this experience, we have
developed the CS test described here.
PeekCS had very good test-retest reliability and
was only slightly less well correlated than the test-
retest of the PRCS test. The PeekCS measurements
were highly correlated with the PRCS test and had
95% limits of agreement, which were equivalent to
around two steps on the PRCS scale. The difference
between the estimated mean CS scores between
PeekCS and PRSC tests was very small and unlikely
to be clinically significant as the upper bound of the
95% CI still only represents approximately one-
seventh of a step in the PRCS test scale.
We believe that PeekCS offers a new CS test with
several useful attributes. Most importantly, the test
performance both in relation to the reference stan-
dard (PRCS) and test-retest is within clinically
acceptable and useful limits. Compared with earlier
mobile-device based CS tests, PeekCS is simple to use,
validated in a relatively large sample with a wide
range of CS.18,19,21–25 It is delivered on the relatively
cheap Android-based smart phone platform. It uses
the Tumbling-E design and therefore is more relevant
to resource limited settings. The test time for PeekCS
(45 seconds per eye) was somewhat shorter than those
reported for other mobile application tests, which
ranged between 53 seconds to several min-
utes.18,19,22,24 PeekCS presents only one randomly
orientated ‘‘E.’’ This avoids crowding effects and the
possibility of learning a sequence if the same chart is
used more than once. It provides an easier testing
scenario for both the observer and the tester than the
PRCS, where multiple letters are presented to the
participant in one chart.
Unlike the gratings-based CS tests, which have
only two choices of target orientation, the PeekCS
provides three-alternative forced choice target orien-
tations, which will reduce guessing and improve
repeatability.24 In the PRCS, the tester usually needs
to point to the letter being tested, whereas in the
PeekCS test the observer only needs to swipe in the
direction indicated by the subject and does not need
to see the letter being tested. This probably increases
tester objectivity. PeekCS provides an automated CS
score calculation. The smartphone’s ambient light
sensor alerts the tester to ambient light levels above a
certain level. Although a smartphone may require
occasional calibration checks, the PeekCS does not
have some limitations of the PR chart such as fading
print, difficulty in maintaining an even illumination,
and reflections from the chart surface, which may
influence the test results, making it a more practical
tool for use in wider settings.36
This study has several limitations. The study was
conducted in people affected by trachoma with
average age of 50 years. This may limit the
generalizability of the study results. In addition, a
detailed ocular examination was not possible in this
study population, as recruitment was conducted in a
community clinic setting. Further validation studies
across different populations and disease groups may
be required. This study was performed using a single
type of smartphone; additional work is needed to
assess the test performance on other handsets. We
used two separate PRCS charts with different random
sequences of the letter ‘‘E’’ for test-retests for each
eye. However, the participants were tested on each
chart twice, which could lead to a potential learning
effect. With regards to PeekCS, the use of a tripod
stand places some limitations on how the test is
deployed. The reliability of the test when deployed on
mobile devices employing display technologies, which
are less sensitive to viewing angle, such as organic
light emitting diode displays, could be investigated.
Similar to the PRCS, the PeekCS only measures
approximation of the CS function (CSF) at one point
(peak), which provides limited information about
frequency-specific deficits.19,25
Overall, PeekCS is a repeatable, rapid, accessible,
and easy to perform CS test that provides results that
are highly comparable with the Pelli-Robson CS test.
It provides a realistic approach for collecting CS
testing data in the most basic of clinical settings,
providing greater insight into an individual’s visual
8 TVST j 2019 j Vol. 8 j No. 5 j Article 13
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experience. Moreover, it may open up new approach-
es to the early detection and monitoring of ocular
disease.
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